The observed rapid and beneficial cardiorenal protective effects mediated by SGLT2 inhibitors is also seen in patients without diabetes, suggesting a mechanism which is unlikely to be mediated by an amelioration in glycemic control [57,60]. Here, SLC5A2 is linked to diabetes mellitus.